Brief: Unicycive Therapeutics Gets Complete Response Letter From FDA On Resubmitted Oxylanthanum Carbonate NDA
30/06/2026 12:11
BRIEF-Unicycive Therapeutics Gets Complete Response Letter From FDA On Resubmitted Oxylanthanum Carbonate NDA June 30 (Reuters) - Unicycive Therapeutics Inc UNCY.O:
RECEIVES COMPLETE RESPONSE LETTER FROM FDA REGARDING RESUBMITTED OXYLANTHANUM CARBONATE (OLC) NEW DRUG APPLICATION (NDA)
FDA RAISES NO CONCERNS ON CLINICAL EFFICACY OR SAFETY DATA, NO ADDITIONAL DATA REQUESTED
FDA HAS NOT CONDUCTED INSPECTION OF THIRD-PARTY MANUFACTURING VENDOR FOR RESUBMITTED NDA
FDA CRL BASED ON THIRD-PARTY MANUFACTURING DEFICIENCIES IDENTIFIED IN JUNE 2025
REMAIN CONFIDENT IN EFFICACY SAFETY OF OLC; OPTIMISTIC THAT WE WILL BE ABLE TO EXPEDITIOUSLY RESUBMIT NDA
Source text: ID:nGNX3zVDRJ
Further company coverage: UNCY.O
((Reutersbriefs@thomsonreuters.com;))
Recent news on Unicycive Therapeutics
See all newsBrief: Unicycive Therapeutics Appoints Meredith Manning To Board Of Directors
Brief: Unicycive Therapeutics Announces Resubmission Of New Drug Application For Oxylanthanum Carbonate
U.S. RESEARCH ROUNDUP-Airbnb, Five Below, Silgan Holdings
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte, CoreWeave
Unicycive rises on narrower quarterly loss